Nicox S.A. (EPA: ALCOX)

Market Cap	20.85M
Revenue (ttm)	3.57M
Net Income (ttm)	-17.36M
Shares Out	69.04M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101,343
Average Volume	153,737
Open	0.296
Previous Close	0.302
Day's Range	0.296 - 0.302
52-Week Range	0.140 - 0.492
Beta	0.82
RSI	54.96
Earnings Date	Jan 24, 2025

About Nicox

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. Nicox S.A. is developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 28
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCOX

Financial Performance

In 2022, Nicox's revenue was 3.27 million, a decrease of -54.78% compared to the previous year's 7.23 million. Losses were -27.76 million, -36.57% less than in 2021.